Mary Beth Harler, new head of IGM autoimmunity and inflammation department (Bristol Myers Squibb)

Top Sanofi vac­cine ex­ecs, Bris­tol My­ers vet chart new path for IG­M's an­ti­bod­ies in in­fec­tious dis­eases, au­toim­mu­ni­ty

When IGM Bio­sciences made its pub­lic de­but two years ago, the S-1 pitch was heav­i­ly cen­tered on how its en­gi­neered IgM an­ti­bod­ies could make po­tent can­cer treat­ments. But it al­so buried a ref­er­ence, deep in­side a sec­tion about the plat­form’s po­ten­tial, about how these an­ti­bod­ies may be ap­plied in a va­ri­ety of con­di­tions — cit­ing au­toim­mune dis­eases and in­fec­tious dis­eases as ex­am­ples.

The biotech is now cre­at­ing new busi­ness units to ex­pand its work in those ex­act ar­eas. And it’s re­cruit­ed a trio of ex­perts from Big Phar­ma to lead them.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.